Terminated × Interventional × Cholangiocarcinoma × Clear all MAST
Phase 1 Terminated
66 enrolled
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Phase 2 Terminated
1 enrolled
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Phase 1/2 Terminated
75 enrolled 17 charts
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Phase 1 Terminated
7 enrolled
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Phase NA Terminated
41 enrolled 14 charts
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Phase 1/2 Terminated
23 enrolled
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase 1 Terminated
25 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Phase 1 Terminated
42 enrolled
FIGHT-302
Phase 3 Terminated
167 enrolled
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Terminated
94 enrolled 28 charts
STARBURST
Phase 2 Terminated
11 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Phase 2 Terminated
1 enrolled
SIRCCA
Phase 2/3 Terminated
89 enrolled 23 charts
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Phase 1 Terminated
54 enrolled
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Phase 2 Terminated
2 enrolled
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
Phase 2 Terminated
20 enrolled
LT for iCCA
Phase 2 Terminated
2 enrolled
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
Phase 1 Terminated
20 enrolled
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
Phase NA Terminated
6 enrolled
ICC
Phase 1/2 Terminated
1 enrolled 11 charts
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase 1/2 Terminated
13 enrolled 24 charts
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
Phase 1 Terminated
5 enrolled
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Phase 2 Terminated
17 enrolled
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Phase 1 Terminated
53 enrolled
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Phase 3 Terminated
48 enrolled 26 charts
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Phase 1 Terminated
8 enrolled 14 charts
EPIC
Phase 2 Terminated
4 enrolled 6 charts
Beacon BNXâ„¢ Endoscopic Ultrasound (EUS)-Needle vs SharkCoreâ„¢ Needle
Phase NA Terminated
376 enrolled
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
Phase 2/3 Terminated
309 enrolled 17 charts
RELEASE
Phase 2 Terminated
41 enrolled 17 charts
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Phase 2 Terminated
2 enrolled 9 charts
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
Phase NA Terminated
21 enrolled 14 charts
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Phase NA Terminated
12 enrolled
MOCHA
Phase 2 Terminated
8 enrolled
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
Phase 1 Terminated
12 enrolled
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Phase 2 Terminated
17 enrolled
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Phase 1 Terminated
27 enrolled
Study of GNS561 in Patients With Liver Cancer
Phase 1/2 Terminated
50 enrolled
BiliFast
Phase NA Terminated
53 enrolled
A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
Phase 2 Terminated
1 enrolled
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Phase 2 Terminated
4 enrolled 9 charts
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Phase 1 Terminated
39 enrolled
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
Phase 1 Terminated
1 enrolled
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Phase 1 Terminated
5 enrolled
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Phase 1 Terminated
85 enrolled 17 charts